InsidersTradesSigma
Track the AIM ImmunoTech Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, AIM ImmunoTech Inc. has recorded 77 reports. Market capitalisation: €7.8m. The latest transaction was filed on 16 March 2026 (C). Among the most active insiders: Equels Thomas K. Every trade is accessible without an account.
77
Insider Decl.
n/a
Thresholds
€450,503
33 ops.
Buy Volume
€854
1 ops.
Sell Volume
58Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 March 2026
Declarations77 total
25,000 shares0Common stockSEC:0001493152-26-010334:0
25,000 shares0Common StockSEC:0001493152-26-010332:0
2,800 shares@ US$1.2328.6% of flowCommon StockSEC:0001493152-26-005620:0
107 shares@ US$7.6970.1% of flowCommon StockSEC:0001641172-25-015207:0
Canonical exit: 11 Sept 2025 (T+90)
103 shares@ US$8.700.1% of flowCommon StockSEC:0001641172-25-015005:0
Canonical exit: 10 Sept 2025 (T+90)
196,851 shares@ US$0.02547.4% of flowCommon StockSEC:0001641172-25-005862:0
Canonical exit: 10 Jul 2025 (T+90)
1,968,504 shares@ US$0.02547.2% of flowCommon StockSEC:0001641172-25-005861:0
Canonical exit: 10 Jul 2025 (T+90)
1,968,504 shares@ US$0.0254100.0% of flowCommon StockSEC:0001641172-25-005860:0
Canonical exit: 10 Jul 2025 (T+90)
41,000 shares@ US$0.0630.4% of flowCommon StockSEC:0001641172-25-002977:0
Canonical exit: 3 Jul 2025 (T+90)
500 shares@ US$0.0870.0% of flowCommon StockSEC:0001641172-25-002827:0
Canonical exit: 3 Jul 2025 (T+90)
44,899 shares@ US$0.1169.0% of flowCommon StockSEC:0001493152-25-010819:0
44,899 shares@ US$0.1168.0% of flowCommon StockSEC:0001493152-25-010821:0
44,899 shares@ US$0.11665.7% of flowCommon StockSEC:0001493152-25-010818:0
50,000 shares@ US$0.13461.0% of flowCommon StockSEC:0001493152-25-009338:0
Canonical exit: 3 Jun 2025 (T+90)
44,000 shares@ US$0.1150.8% of flowCommon StockSEC:0001493152-25-009164:0
Canonical exit: 2 Jun 2025 (T+90)
19,290 shares@ US$0.13534.3% of flowCommon StockSEC:0001493152-25-009020:0
38,580 shares@ US$0.1358.3% of flowCommon StockSEC:0001493152-25-009015:0
38,580 shares@ US$0.1359.4% of flowCommon StockSEC:0001493152-25-009013:0
83,334 shares@ US$0.121.5% of flowCommon StockSEC:0001493152-25-009003:0
Canonical exit: 2 Jun 2025 (T+90)
43,330 shares@ US$0.12028.3% of flowCommon StockSEC:0001493152-25-007740:0
27,412 shares@ US$0.198.4% of flowCommon StockSEC:0001493152-25-007738:0
25,797 shares@ US$0.20198.3% of flowCommon StockSEC:0001493152-25-007739:0
43,330 shares@ US$0.12029.3% of flowCommon StockSEC:0001493152-25-007578:0
43,330 shares@ US$0.12028.3% of flowCommon StockSEC:0001493152-25-007579:0
25,797 shares@ US$0.20199.4% of flowCommon StockSEC:0001493152-25-004670:0
25 of 77 declarations
关于 AIM ImmunoTech Inc.
AIM ImmunoTech Inc. 是一家总部位于美国的免疫制药公司，在美国的NYSE American市场上市。对于投资者而言，它属于更广泛的美国交易所体系，包括纽约证券交易所（NYSE）和纳斯达克（NASDAQ）。该公司总部位于佛罗里达州奥卡拉，专注于癌症、病毒性疾病和免疫失调适应症的免疫调节疗法的研究和临床开发。其主要资产是Ampligen®（rintatolimod），AIM将其描述为一种广谱免疫调节剂。([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai)) AIM的业务概况是一家处于开发阶段的生物技术公司，而非多元化的商业制药公司。历史上，该公司通过推进主要平台进行临床试验、获得孤儿药和其他监管认定，以及扩展多种适应症的证据基础来建立其估值故事。这种模式为积极的临床结果带来了杠杆作用，但也意味着投资案例高度依赖于试验执行、资金获取和监管进展。最近的文件和公司发布显示，公司战略重点放在胰腺癌上，同时Ampligen也在其他实体瘤和某些病毒/病毒后疾病中进行探索。([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai)) 目前最重要的项目是Ampligen在晚期胰腺癌中的应用，包括将Ampligen与阿斯利康的Imfinzi®（durvalumab）联合使用的DURIPANC研究。AIM报告了2025年积极的临时安全性和有效性更新，并于2026年4月表示，它正在进入一个关键的价值拐点阶段，并计划进行一项3期研究。该公司还强调了Ampligen在美国和欧洲获得胰腺癌孤儿药认定，并表示计划在日本寻求类似的地位。([aimimmuno.com](https://aimimmuno.com/aim-immunotech-posts-virtual-investor-key-opinion-leader-segment-spotlighting-ampligen-breakthrough-data-in-pancreatic-cancer/?utm_source=openai)) 从产品角度来看，AIM几乎完全围绕Ampligen展开，而不是拥有广泛的市场产品组合。该公司描述了Ampligen在胰腺癌、其他实体瘤、严重慢性疲劳综合征以及与COVID相关或COVID后疾病（包括ME/CFS）中的应用案例。它还提到了在荷兰伊拉斯谟医学中心的早期获取计划以及在国际研究环境中的临床活动。这种地域足迹使该公司拥有适度的全球影响力，但其运营中心仍在美国，总部设在佛罗里达州。([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai)) 近期公司里程碑包括2025年第三季度财务业绩、胰腺癌开发的持续进展、2026年3月与赛默飞世尔科技PPD部门达成协议以协助设计预期的3期试验、2026年初宣布的配股，以及2026年5月发布的虚拟投资者演示文稿，其中强调了更新的胰腺癌数据。对于讲法语的投资者而言，AIM应被视为一个高度投机的微型生物技术故事，其上涨空间与临床数据和监管里程碑相关，而稀释风险和二元试验结果仍然是核心考虑因素。([aimimmuno.com](https://aimimmuno.com/aim-immunotech-reports-third-quarter-2025-financial-results-and-highlights-continued-progress-across-pipeline-with-strategic-focus-on-pancreatic-cancer-clinical-program/?utm_source=openai))
